(J Thorac Cardiovasc Surg
“Background. Little is known about the effects of adult attention Salubrinal deficit hyperactivity disorder (ADHD) on work performance or accidents-injuries.
Method. A survey was administered in 2005 and 2006 to employees of a large manufacturing firm to assess the prevalence and correlates of adult ADHD. Respondents (4140 in 2005, 4423 in 2006, including 2656 in both surveys) represented 35-38% of the workforce. ADHD was assessed with the World Health Organization (WHO) Adult ADHD Self-Report Scale (ASRS), a validated screening scale for DSM-IV adult ADHD. Sickness absence, work performance and workplace accidents-injuries were assessed with the WHO Health and Work Performance Questionnaire (HPQ).
Results. The estimated current prevalence (standard error) of DSM-IV ADHD was 1.9% (0.4). ADHD was associated with a 4-5% reduction in work performance (chi(2)(1) = 9.1, p = 0.001), a 2.1 relative-odds of sickness absence (chi(2)(1)
= 6.2, p = 0.013), and a 2.0 relative-odds of workplace accidents-injuries (chi(2)(1) = 5.1, p = 0.024). The human capital value (standard error) of the lost work performance associated with ADHD totaled US$4336 (676) per worker with ADHD in the year before interview. No data were available to monetize other workplace costs of accidents-injuries (e.g. destruction of equipment). Only a small minority of workers with ADHD were in treatment.
Conclusions. Adult ADHD is a significantly impairing condition among workers. Given the low rate of treatment and high human capital costs, in conjunction Selleck Combretastatin A4 with evidence from controlled trials that treatment can reduce ADHD-related impairments, ADHD Would seem to be a good candidate for workplace trials that
evaluate treatment cost-effectiveness from the employer’s perspective.”
“Introduction: We previously demonstrated MORF/cMORF pretargeting of human islets and betalox 5 cells (a human beta cell line) ZD1839 chemical structure transplanted subcutaneously in mice with the anti-human islet antibody, HPil. We now compare pretargeting with direct targeting in the beta cell transplant model to evaluate the degree to which target/non-target (T/NT) ratios may be improved by pretargeting.
Methods: Specific binding of an anti-human islet antibody HPil to the beta cells transplanted subcutaneously in mice was examined against a negative control antibody. We then compared pretargeting by MORF-HPil plus In-111-labeled cMORF to direct targeting by In-111-labeled HPil.
Results: HPil binding to betalox5 human cells in the transplant was shown by immunofluorescence. Normal organ In-111 backgrounds by pretargeting were always lower, although target accumulations were similar. More importantly, the transplant to pancreas and liver ratios was, respectively, 26 and 10 by pretargeting as compared to 9 and 0.6 by direct targeting.